company background image
MRUS logo

Merus NasdaqGM:MRUS Stock Report

Last Price

US$53.40

Market Cap

US$3.6b

7D

3.1%

1Y

153.1%

Updated

11 Oct, 2024

Data

Company Financials +

Merus N.V. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Merus
Historical stock prices
Current Share PriceUS$53.40
52 Week HighUS$61.61
52 Week LowUS$19.81
Beta1.11
11 Month Change6.21%
3 Month Change-6.74%
1 Year Change153.08%
33 Year Change72.87%
5 Year Change225.41%
Change since IPO431.87%

Recent News & Updates

We're Hopeful That Merus (NASDAQ:MRUS) Will Use Its Cash Wisely

Sep 20
We're Hopeful That Merus (NASDAQ:MRUS) Will Use Its Cash Wisely

Merus N.V.'s Innovative Cancer Therapies: Balancing Its IP Potential With Financial Risks

Aug 14

Recent updates

We're Hopeful That Merus (NASDAQ:MRUS) Will Use Its Cash Wisely

Sep 20
We're Hopeful That Merus (NASDAQ:MRUS) Will Use Its Cash Wisely

Merus N.V.'s Innovative Cancer Therapies: Balancing Its IP Potential With Financial Risks

Aug 14

Analysts Just Made A Major Revision To Their Merus N.V. (NASDAQ:MRUS) Revenue Forecasts

Jun 01
Analysts Just Made A Major Revision To Their Merus N.V. (NASDAQ:MRUS) Revenue Forecasts

Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy)

May 24

Earnings Beat: Merus N.V. (NASDAQ:MRUS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

May 12
Earnings Beat: Merus N.V. (NASDAQ:MRUS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Merus (NASDAQ:MRUS) Is In A Good Position To Deliver On Growth Plans

May 10
Merus (NASDAQ:MRUS) Is In A Good Position To Deliver On Growth Plans

Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement

Mar 01

Merus N.V.'s (NASDAQ:MRUS) Shares Climb 30% But Its Business Is Yet to Catch Up

Feb 01
Merus N.V.'s (NASDAQ:MRUS) Shares Climb 30% But Its Business Is Yet to Catch Up

Merus Stock: Rally Seems Overdone

Jan 23

Are Investors Undervaluing Merus N.V. (NASDAQ:MRUS) By 45%?

Jan 14
Are Investors Undervaluing Merus N.V. (NASDAQ:MRUS) By 45%?

Risks To Shareholder Returns Are Elevated At These Prices For Merus N.V. (NASDAQ:MRUS)

Dec 18
Risks To Shareholder Returns Are Elevated At These Prices For Merus N.V. (NASDAQ:MRUS)

We Think Merus (NASDAQ:MRUS) Needs To Drive Business Growth Carefully

Sep 19
We Think Merus (NASDAQ:MRUS) Needs To Drive Business Growth Carefully

Merus N.V.'s (NASDAQ:MRUS) Business Is Yet to Catch Up With Its Share Price

Jun 20
Merus N.V.'s (NASDAQ:MRUS) Business Is Yet to Catch Up With Its Share Price

Is Merus (NASDAQ:MRUS) In A Good Position To Invest In Growth?

May 24
Is Merus (NASDAQ:MRUS) In A Good Position To Invest In Growth?

Merus N.V. (NASDAQ:MRUS) Shares Could Be 26% Below Their Intrinsic Value Estimate

Feb 08
Merus N.V. (NASDAQ:MRUS) Shares Could Be 26% Below Their Intrinsic Value Estimate

Merus GAAP EPS of -$0.13 beats by $0.49, revenue of $12.68M beats by $2.23M

Aug 08

Merus N.V. initiated with Buy at Stifel based on three bispecific antibodies

Aug 02

Merus: Precision Oncology Pioneer Continues To Execute In The Clinic

Jun 30

Need To Know: Analysts Are Much More Bullish On Merus N.V. (NASDAQ:MRUS)

May 14
Need To Know: Analysts Are Much More Bullish On Merus N.V. (NASDAQ:MRUS)

Merus (NASDAQ:MRUS) Is In A Strong Position To Grow Its Business

Apr 25
Merus (NASDAQ:MRUS) Is In A Strong Position To Grow Its Business

New Forecasts: Here's What Analysts Think The Future Holds For Merus N.V. (NASDAQ:MRUS)

Mar 03
New Forecasts: Here's What Analysts Think The Future Holds For Merus N.V. (NASDAQ:MRUS)

We're Not Worried About Merus' (NASDAQ:MRUS) Cash Burn

Nov 25
We're Not Worried About Merus' (NASDAQ:MRUS) Cash Burn

News Flash: Analysts Just Made A Sizeable Upgrade To Their Merus N.V. (NASDAQ:MRUS) Forecasts

Aug 08
News Flash: Analysts Just Made A Sizeable Upgrade To Their Merus N.V. (NASDAQ:MRUS) Forecasts

Calculating The Intrinsic Value Of Merus N.V. (NASDAQ:MRUS)

Jul 28
Calculating The Intrinsic Value Of Merus N.V. (NASDAQ:MRUS)

We're Not Very Worried About Merus' (NASDAQ:MRUS) Cash Burn Rate

Jul 02
We're Not Very Worried About Merus' (NASDAQ:MRUS) Cash Burn Rate

Shareholder Returns

MRUSUS BiotechsUS Market
7D3.1%0.3%1.2%
1Y153.1%19.7%31.9%

Return vs Industry: MRUS exceeded the US Biotechs industry which returned 19.7% over the past year.

Return vs Market: MRUS exceeded the US Market which returned 31.9% over the past year.

Price Volatility

Is MRUS's price volatile compared to industry and market?
MRUS volatility
MRUS Average Weekly Movement4.2%
Biotechs Industry Average Movement9.8%
Market Average Movement6.4%
10% most volatile stocks in US Market14.9%
10% least volatile stocks in US Market3.1%

Stable Share Price: MRUS has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: MRUS's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2003201Bill Lundbergwww.merus.nl

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma.

Merus N.V. Fundamentals Summary

How do Merus's earnings and revenue compare to its market cap?
MRUS fundamental statistics
Market capUS$3.59b
Earnings (TTM)-US$167.66m
Revenue (TTM)US$35.19m

103.5x

P/S Ratio

-21.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MRUS income statement (TTM)
RevenueUS$35.19m
Cost of RevenueUS$165.20m
Gross Profit-US$130.00m
Other ExpensesUS$37.66m
Earnings-US$167.66m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.46
Gross Margin-369.41%
Net Profit Margin-476.41%
Debt/Equity Ratio0%

How did MRUS perform over the long term?

See historical performance and comparison